Antidote Partners with SEQSTER to Accelerate Patient Identification & Enrollment for Clinical Trials
2024年7月8日 - 9:00PM
ビジネスワイヤ(英語)
Delivering Patient Matching, Real-Time Data
Access, and Diversity in Clinical Research for Pharma and Life
Science Companies
SEQSTER PDM Inc. (“SEQSTER”), the leading patient-centric
healthcare technology company, and Antidote Technologies
(“Antidote”), a digital health company that focuses on patient
engagement to accelerate recruitment for clinical trials, today
announced a partnership to enhance patient identification,
improving trial timelines and enrollment outcomes for Pharma and
Life Science companies with their fully integrated end-to-end
solution.
By leveraging the SEQSTER Operating System, Antidote can more
accurately match patients to clinical trials based on a 360° view
of their medical history, genomic data, and lifestyle factors.
Pairing this solution with Antidote’s best-in-class screening and
patient support services enables the acceleration of recruitment
with better quality patients and provides those patients with a
more accurate match for potential clinical trials that they may
qualify for.
“By integrating SEQSTER’s Operating System with Antidote's
precision recruitment capabilities, we are creating a powerful
synergy that addresses one of the most pressing challenges in
clinical research today: clinical trial recruitment plus
engagement. This partnership empowers us to accelerate patient
recruitment while providing a comprehensive, real-time view of
study participant health data, accelerating the path to medical
breakthroughs,” stated Ardy Arianpour, CEO & Co-Founder of
SEQSTER.
“Our mission at Antidote has always been to connect the right
patients with the right trials, striking a balance between advanced
technology and a personal touch. Partnering with SEQSTER allows us
to enhance our precision recruitment process with unparalleled data
integration capabilities, ensuring that we can more effectively
identify suitable participants and reduce the time it takes to
bring new treatments to market. Together with SEQSTER, we will
transform the clinical trial landscape, making it more efficient,
inclusive, and patient-centered,” explained Samantha Veeck, Co-CEO
of Antidote.
With SEQSTER’s comprehensive data integration capabilities and
Antidote’s extensive partner network and robust contact center for
patient support, this partnership fosters diversity in drug
development, a growing priority for the FDA. Underserved
populations often face barriers to participation in clinical
trials, such as lack of access to information and logistical
challenges. By providing access to patient medical records, the
collaboration ensures better representation of underserved
populations in clinical trials. This not only meets new FDA
diversity requirements but also improves the generalizability of
research findings and addresses healthcare disparities. The
integration of SEQSTER’s and Antidote’s technologies streamlines
the patient enrollment process, reducing the time it takes to start
trials, which is particularly beneficial for urgent clinical
studies. Furthermore, Antidote’s focus on personalized patient and
site services, combined with SEQSTER’s technology, enhances patient
engagement, leading to better adherence to trial protocols and more
accurate data collection.
About Antidote
Antidote Technologies is a digital health company with a mission
to catalyze medical innovation by successfully connecting patients
and researchers as the best-in-class recruiter for clinical
studies. Its precision recruitment strategy for clinical trials
meets patients where they are, leading to high-quality referrals,
reduced site burden, and efficient enrollment. This is made
possible by a unique, high-tech, high-touch approach and the
largest global partnership network of its kind. Antidote provides
patient-centric clinical search technology to hundreds of patient
advocacy groups and research foundations at no cost in order to
advance medical breakthroughs and increase clinical trial
participation. They also configure their search platform for
sponsors, health systems, and other providers to ensure an optimal
experience for patients looking to participate in their portfolio
of clinical trials.
To learn more about Antidote, please visit
http://www.antidote.me.
ABOUT SEQSTER
SEQSTER is the leading healthcare technology company that breaks
down health data silos at scale. Its enterprise operating system
aggregates disparate health data sources into a single, 360-degree
view of a patient in real-time, solving a multitude of challenges
for life sciences, patient engagement and data
interoperability.
SEQSTER has nationwide coverage of EHRs from hospitals and
medical groups, genomic DNA, wearables, pharmacy and social
determinants of health data. Through its customizable white-label
approach, SEQSTER provides accelerated access to de-identified,
tokenized, real-time data and comprehensive curated data to address
critical needs across the healthcare continuum. SEQSTER is
privately held and headquartered in San Diego.
To learn more about the SEQSTER Operating System for Clinical
Studies, Patient Registries and the Digital Front Door, please
contact us at info@seqster.com or visit www.seqster.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708769797/en/
Amanda McDowell Senior Manager, Content and Communications
Antidote Technologies amanda.mcdowell@antidote.me
Bill Douglass press@seqster.com